SHAREHOLDER UPDATE:  Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. – DMTX

 

BALA CYNWYD, October 13, 2017 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Dimension Therapeutics, Inc. (“Dimension” or “the Company”) (Nasdaq- DMTX-News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to REGENXBIO, Inc. (“REGENXBIO”).

Under the terms of the transaction, Dimension shareholders will receive only 0.1573 of a share of REGENXBIO stock for each share of Dimension stock they own. The transaction values Dimension at only approximately $3.41 per share. The investigation concerns whether the Board of  Dimension breached their fiduciary duties to shareholders and whether REGENXBIO is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Dimension shareholders. For example, shares of Dimension stock have traded at $51.65 per share and an analyst has set an $12.00 per share price target for Dimension stock.

If you own shares of Dimension stock and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or calling toll  free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.